DIFFUSION MRI AND CHEMOTHERAPEUTIC RESPONSE

描述（摘自摘要）：这项拟议研究的假设是 弥散磁共振成像，测量组织的表观弥散系数， 水（ADCw）有可能成为有效癌症的非侵入性标志物 化疗大量临床前证据表明，ADCw 对成功的化疗有反应的肿瘤的增加， 如果治疗无效，它也不会改变。据信 ADCw的这些局部变化是细胞凋亡早期阶段的结果。的 该提案将在临床环境中测试该假设。乳腺癌患者 正在接受泰索帝治疗的转移性肝脏病变患者， 在开始给药前和给药后5-30天进行弥散MRI检查 疗法将获得弥散和T2加权图像。患者将 跟踪44天，以确定他们的反应程度的目标和 主观临床标准。这项试验将证明扩散是否 图像可以预测对治疗的最终反应

DESCRIPTION (taken from abstract): The hypothesis of this proposed study is that diffusion MRI, which measures the apparent diffusion coefficient of tissue water (ADCw) has potential to be a non-invasive marker for effective cancer chemotherapy. A significant amount of pre-clinical evidence has shown that ADCw increases in tumors that are destined to respond to successful chemotherapy, and that it does not change if the therapy is ineffective. It is believed that these local changes in ADCw result from the early stages of apoptosis. The proposal will test the hypothesis in a clinical setting. Breast cancer patients with metastatic liver lesions who are undergoing taxotere therapy will be examined by diffusion MRI prior to, and 5-30 days after, commencement of therapy. Diffusion and T2-weighted images will be obtained. Patients will be followed for 44 days to dteermine the extent of their response by objective and subjective clinical criteria. This trial will demonstrate whether diffusion images predict the final response to therapy.